Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity
Emily C. Sullivan, Nabil Saleem, Areeba A. Hashmi, Kristopher A. Knight, Austre Y. Schiaffino Bustamante, Ahmed A. Aljudi, Brandon J. Fanelli, Sunil S. Raikar · 2026
Read Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity by Emily C. Sullivan, Nabil Saleem, Areeba A. Hashmi, Kristopher A. Knight, Austre Y. Schiaffino Bustamante, Ahmed A. Aljudi, Brandon J. Fanelli, Sunil S. Raikar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13664042.txt.
Description
Emily Sullivan and co-authors build a dual-target CAR T-cell plan against acute myeloid leukemia. The disease is the deadliest leukemia in children and adults alike, and cell therapy stalls when tumor cells vary in their surface marks. Two marks, CD33 and CD70, anchor the team's attack.
In their 2026 study, a leukemia cell line was edited into sublines that carry one mark, the other, or both, to mimic real tumor variety. Two dual products were made: a pooled mix of single-mark cells, and cells carrying both receptors at once. Both products killed all sublines well, while single-mark cells failed when their mark was gone. Mouse tests extend the proof.
Catalog record
| CREATOR | Emily C. Sullivan, Nabil Saleem, Areeba A. Hashmi, Kristopher A. Knight, Austre Y. Schiaffino Bustamante, Ahmed A. Aljudi, Brandon J. Fanelli, Sunil S. Raikar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |